The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.
A new player has entered the liquid biopsy game.
Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Venture funding drops again, but there’s no need to panic yet.
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
The J&J-Auris tie-up will yield a huge return for investors who went in big.